for dual indications under the U.S. Food & Drug Administration’s (FDA) Animal Efficacy Rule as a pivotal-stage radiation countermeasure, and under the FDA’s traditional drug approval pathway as a targeted cancer treatment.
•
The FDA granted entolimod both Fast Track and Orphan Drug status for reducing the risk of death following a potentially lethal dose of total body irradiation during or after a radiation disaster.